Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-operative cetuximab dose-finding study before curative treatment of colorectal liver metastases
NL-OMON47303Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab in colorectal cancer liver metastasis (CRLM) (4 arms), sponsored by Vrije University Medical Center. Primary endpoints: Reduction in circulating tumor cells and Minimal effective dose of cetuximab. Started Jan 2017; status: active, not recruiting.
02
Drugs
cetuximab
03
Conditions
colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on NL-OMON47303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47303.